2026 Interim report
Filed with HKEX · Stock code 9877 · · 53 pages · English
2 Defi nitions 5 Corporate Information 7 Financial Highlights 8 Business Overview 11 Management Discussion and Analysis 25 Other Information 37 Interim Condensed Consolidated Statement of Profi t or Loss and Other Comprehensive Income 38 Interim Condensed Consolidated Statement of Financial Position 39 Interim Condensed Consolidated Statement of Changes in Equity 40 Interim Condensed Consolidated
Jenscare Scientific Co. Ltd. on 6ix
Earlier from Jenscare Scientific
- VOLUNTARY ANNOUNCEMENT The Registration Approval of JensClip by NMPA and Its Active Commercialization
- Jenscare released its multi-product portfolio's, including LuX-Valve Plus TRINITY study, JensClip and Ken-Valve, remarkable clinical outcomes at TCT 2025 in the U.S.
- LuX-Valve Plus Approved for Hong Kong-Macao Medicine and Equipment Connect
- Jenscare, releases 2025H1 interim results
- Jenscare Announces 2025H1 Interim Results
Later from Jenscare Scientific
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Voluntary announcement presentation of the 6-month follow-up results of travel iii and the 2-year follow-up results of travel ii of the lux-valve plus clinical study at tct 2026 in the united states
Follow Jenscare Scientific into a list and get an email when it puts out news.
Follow Jenscare Scientific